The FDA announced on Sept. 9, 2021, that Jacobus Pharmaceutical Company Inc. voluntarily recalled Ruzurgi (amifampridine) Tablets 10 mg due to microbial contamination risks. The Class I recall affects 2,324 bottles distributed in the USA and Canada.
How to tell if you have it
- Brand: Jacobus Pharmaceutical
- Product: Ruzurgi (amifampridine) Tablets 10 mg
- Packaging: 100-count bottles
- NDC: 49938-110-01
- Lot codes: 18038, 18039 (Exp 03/2023); 18079 (Exp 05/2023)
- Quantity: 2,324 bottles
The hazard
The FDA stated that the firm's testing found lots exceeded specifications for aerobic bacteria, yeast, and mold counts. This microbial contamination of non-sterile products poses a health risk to consumers.
Context
GovInfoNow records show other recent recalls include Fresenius Kabi Famotidine Injection (2025-11-06) and JB Chemicals Cetirizine Tablets (2026-06-24). Alembic also recalled Fesoterodine Tablets on 2025-12-16 due to impurity risks.